ORIC vs JBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ORIC · Oric Pharmaceuticals$8.82 ▲ 3.89%
JBIO · Jade Biosciences$15.07 ▲ 6.88%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ORIC -29.2%
- JBIO +62.4%
Head to head
| Metric | ORIC | JBIO |
|---|---|---|
| Price | $8.82 | $15.07 |
| Change today | ▲ 3.89% | ▲ 6.88% |
| Market cap | $914.22M | $958.41M |
| Return, 3 months | -35.2% | -30.6% |
| Return, year to date | +7.8% | -2.3% |
| Return, 1 year | -28.6% | +64.0% |
| P/E (TTM) | -6.8 | -14.1 |
| P/B | 2.4 | 2.2 |
| P/E percentile vs own 5y | 12th | 3rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -14.1% | -73.5% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -39.8% | -47.8% |
| Analyst target vs. price | +167.1% | +235.1% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 35 | 52 |
| 30-day volatility | 129.0% | 49.8% |
| Max drawdown, 1 year | -46.1% | -50.1% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JBIO is the largest of the group by market value.
- JBIO has returned the most over the past year.
- JBIO carries the lowest trailing P/E.
- JBIO has been the calmest stock over the last 30 days.